This study demonstrated that monitoring EGFR mutation levels or changes in blood could be a meaningful approach to predict clinical response and progression for lung EGFR mutation-positive adenocarcinoma patients treated with TKI therapy. This evidence concerns the gene EGFR and adenocarcinoma.